(Q38094782)

28 August 2017

Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer (English)

1 reference

28 August 2017

1 reference

Valerie Nelson

1

1 reference

28 August 2017

Jessica K Altman

series ordinal

2

1 reference

28 August 2017

Leonidas C Platanias

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

2 April 2013

1 reference

Expert Opinion on Investigational Drugs

28 August 2017

1 reference

28 August 2017

22

1 reference

28 August 2017

6

1 reference

28 August 2017

715-722

1 reference

PI3K in lymphocyte development, differentiation and activation

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Phosphoinositide signalling in cancer: beyond PI3K and PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

mTOR, translation initiation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Activation of AKT kinases in cancer: implications for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Distinct biological roles for the akt family in mammary tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

The evolution of the TOR pathway and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Mechanisms of sarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Renal-cell carcinoma--molecular pathways and therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

The genetic basis of kidney cancer: a metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Signaling pathways in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

21 January 2018

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Mechanisms governing the control of mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

A unifying model for mTORC1-mediated regulation of mRNA translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

TOR complex 2: a signaling pathway of its own.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Hypoxia, MTOR and autophagy: converging on senescence or quiescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Targeting mTOR globally in cancer: thinking beyond rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

An overview of the mTOR pathway as a target in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Use of sirolimus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Targeting mTOR for the treatment of AML. New agents and new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Defining the role of TORC1/2 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

PI3K/AKT/mTOR Pathway in Angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.787066

10.1517/13543784.2013.787066

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference